Sustained Release Excipients Market: Market Size & Forecast 2026

Sustained release excipients are inactive ingredients engineered to extend the therapeutic action of a drug by controlling how the active pharmaceutical ingredient is released over time. These include polymers such as PLGA, hydroxypropyl methylcellulose, ethyl cellulose, and lipid or wax matrices used in oral, injectable, and topical formulations. The market sits at the intersection of formulation science and advanced drug delivery, supporting both small-molecule and biologic products across regulated and emerging therapeutic areas.

• •Global market size estimated at $1.6 billion in 2025, with a 7.65% CAGR.
• •Closely related controlled-release and hydrogel-based delivery markets are projected to exceed $12 billion by 2030 at around 7.6% CAGR.
• •Demand is reinforced by USFDA-approved parenteral peptide formulations that rely on polymeric microsphere excipient platforms.

The principal growth driver is the rising pipeline of complex generics and biologics, where sustained release profiles improve efficacy, reduce dosing frequency, and support patient adherence. Expanding applications in peptide and protein therapeutics, which are forecast to exceed $100 billion globally by 2030, are accelerating demand for biocompatible polymer carriers and microsphere technologies. Additional momentum comes from nutraceutical formulations and personalized 3D-printed dosage forms that require tailored excipient systems.

• •Protein and peptide therapeutic markets projected to surpass $100 billion by 2030, fueling excipient demand.
• •Biopharmaceutical formulation segment expanding at roughly 8.87% CAGR from 2025 to 2030.
• •Complex nutraceutical products and 3D-printed personalized medicines are opening new excipient application areas.

Segmentation is typically defined by excipient type (polymers, lipids, surfactants, and others), dosage form (oral, parenteral, topical, transdermal), and end-user application (large pharma, generics, nutraceuticals). North America leads due to a concentration of FDA-approved peptide and complex injectable products, while Europe benefits from strong generic and biosimilar manufacturing. Asia-Pacific is the fastest-growing region, supported by expanding pharmaceutical production capacity in India, China, and South Korea and rising demand for advanced generics.

• •Polymers and lipid-based carriers dominate the excipient type segment.
• •Parenteral and oral controlled-release formats account for the largest share of formulation adoption.
• •Asia-Pacific shows the strongest growth rate, with North America holding the largest revenue share.

What are the recent trends and outlook?

Key trends include the migration of sustained release technology from small molecules into peptide, protein, and nucleic acid therapeutics, as well as integration with nanoemulsion, hydrogel, and additive manufacturing platforms. Personalized medicine initiatives are pushing demand for customizable excipient blends tailored to individual pharmacokinetic profiles. Through 2030, the market is expected to benefit from continued biologics approvals, growth in long-acting injectables, and broader adoption of patient-centric formulation strategies.

• •Sustained release excipients are increasingly used in long-acting injectable and depot formulations.
• •Nanoemulsion and 3D printing platforms are expanding the addressable applications for sustained release excipients.
• •Regulatory support for complex generics and 505(b)(2) development pathways is expected to sustain mid-single-digit to high-single-digit growth through 2030.